Anti-Contraction Effects of Euscaphic Acid Isolated from
Crataegus azarolus var. aronia L on Rat’s Aortic Smooth Muscle

Omar A.M Al-Habib 1*, Sarbasta A. Mahmud 2, Giovanni Vidari 3

1. Biology Department, Faculty of Science, University of Zakho, Zakho, Kurdistan Region-Iraq
2. Biology Department, Faculty of Science, Soran University, Soran, Kurdistan Region-Iraq
3. Dipartimento di Chimica e Centro CISTRE dell’Università di Pavia, Via Taramelli 12, 27100 Pavia, Italy

Abstract

The current study represents the first attempt to investigate the effect of the Euscaphic acid (EA) on Rats isolated thoracic aortic smooth muscle cells. Isolated aorta was used to test the anti-contraction effects and the possible mode of action(s) of the EA (1*10⁻³ M) and (3*10⁻³ M) isolated from Crataegus azarolus var. aronia L. Euscaphic acid showed high anti-contraction effects on norepinephrin (NE), (1*10⁻³ - 10⁻³ M) induced contraction in aortic smooth muscle cells in endothelium-intact, endothelium-denuded, and aortic rings pre-incubated with potassium (K⁺)-channels blocker (tetraethylammonium, TEA), prostaglandin I₂ (PGI₂) inhibitor (indomethacin) and cyclic guanosine monophosphate (cGMP) inhibitor (methylene blue). On the other hand, other K⁺ channels subtype blockers glibenclamide (GLIB); barium chloride (BaCl₂) and 4-aminopyridine (4-AP) demonstrated that adenosine triphosphate sensitive K⁺(K₁ATP), inwardly rectifying K⁺(Kᵣ) and voltage-dependent K⁺(Kᵥ) channels played no role in anti-contraction induced by EA. Furthermore, the role of L-types calcium (Ca²⁺) channels in EA anti-contractile effects on aortic smooth muscle cells was proved, by using the Ca²⁺-channel blocker verapamil, as indicated by the production of a potent anti-contraction effect. The results of the current study indicate that the anti-contraction effects of EA may be due to the activation of calcium dependent, K⁺(Kᵥ) channels and blocking of L-type Ca²⁺ channels. Thus, from these results it can be concluded that both K⁺ and Ca²⁺ channels play an important role in anti-contraction effects of EA, which are mediated possibly through opening of Kᵥ channels and blockade of voltage-dependent calcium channels, which may justify the use of medicinal plant C. azarolus in cardiovascular disease.

Keywords: Crataegus azarolus var. aronia, Euscaphic acid, smooth muscle cells, K⁺-channels blockers, Ca²⁺-channels blocker.

1- Introduction

Medicinal herbs form an important part of folk medicine in most countries with a vital importance in treatment procedures (Rezaei et al., 2014). The use of alternative medicines is well documented in patients with chronic diseases such as hypertension, acute coronary syndrome, coronary heart disease, heart failure, peripheral arterial disease, and stroke (Charoonratana et al., 2014).

Medicinal plants represent good sources for new, safe, biodegradable and renewable drugs and according to the World Health Organization (WHO) report (1993), about 65-80% of the developing countries populations depend essentially on plants and plant derived compounds for their primary healthcare needs (Rojas et al., 2014). In modern pharmacy, about 50% of drugs are natural products derived from plants (Dhami, 2013). The newest drug discovery projects adoption based on traditional medicinal plant strategy to assure their safety uses (Dhami, 2013; Mishra and Tiwari, 2011). In folk medicine, Hawthorn leaves, flowers and fruits are important parts of the plant used as coronary vasodilator, cardioactive, and hypotensive remedies (Keser et al., 2014), and their phytochemical and pharmaceutical importance are reflected by the presence of bioactive compounds such as phenols, flavonoids, alkaloids, steroids, terpenoids and tannins in medicinal herbs and plants (Mirzai and Mirzaei, 2013).

The positive effects of Crataegus azarolus on the cardiovascular system have recently received a great scientific attention in phytotherapy (Caliskan et al., 2012). Bioactive compounds present in hawthorn include aromatic amines, essential oils, phenolic acids, flavonoids, proanthocyanidins (Keser et al., 2014) and triterpenes (Hu et al., 2014). In vitro and in vivo pharmacological investigations revealed that Euscaphic acid has a variety of biological activities, such as inhibitory effect against protein tyrosine phosphatase 1B (Li et al., 2014), enzymes involved in DNA replication (Jung et al., 2005), and lipid peroxidation (Marzouk, 2009). Furthermore, it can inhibit atherosclerosis and xanthoma (Zhang et al., 2006), and decrease intracellular melanin content (Song et al., 2013). In addition, Euscaphic acid has diuretic, hepatoprotective (Lee et al., 2009), anti-hyperglycemic, and antitumor-promoting (Kim et al., 2012), and antinociceptive properties (Jovel et al., 2007). However, since EA has been isolated for the first time from C. azarolus and no attempt has been made so far to study its effect on smooth muscle physiology, the present study aimed to investigate the anti-contraction effects of EA on a rat’s aortic smooth muscle cells with emphases on the role of endothelium-derived relaxing factors, Ca²⁺ and K⁺ channels in its anti-contraction effects.

48
2- Materials And Methods

Euscaphic acid from Crataegus aronia

Euscaphic acid (Jacaranoic acid) was isolated for the first time from C. azarolus ethyl acetate fraction, purified and identified after several analytical processes, including TLC (direct and reverse phase), column chromatography, $^1$H and $^{13}$C NMR spectra, ESI-MS spectrum etc. Detailed purification and identification procedures are fully described by Mahmoud et al., (2015).

Albino Rats

Adult male albino rats, Rattus norvegicus weighing 200 – 300 gs, used in the current study were bred in the Animal House, Department of Biology, Faculty of Science / University of Zakho and maintained in plastic cages (460 x 30 x 20 cm). They were kept under standard laboratory conditions at 22 ± 2 °C and exposed to a photoperiod of 12 hrs light followed by 12 hrs of darkness, using an automated light-switching devise. The rats were fed on standard rat pellets with free access to dechlorinated tap water ad libitum.

Aorta Preparation and Experimental Protocols

The rats were injected intraperitoneally (IP) with heparin, (1500 units/kg body weight) and left for 30 min to avoid blood clotting and possible damage of endothelial layer of the aorta, and then anesthetized with ketamine (40 mg/kg) and Xylazine (10 mg/Kg) intraperitoneally. The chest cavity was opened, aorta was isolated and transferred into a petri-jar containing Krebs or calcium free Krebs solution, aerated with carbogen (95% O2 and 5% CO2) and maintained in a water bath at 37 °C. The aorta cut into rings of about 2-4 mm long and the first four rings of the aorta distal to aortic arch were taken to avoid the difference in the amplitude of contraction. The rats were injected intraperitoneally (IP) with heparin, (1500 units/kg body weight) and left for 30 min to avoid blood clotting and possible damage of endothelial layer of the aorta, and then anesthetized with ketamine (40 mg/kg) and Xylazine (10 mg/Kg) intraperitoneally. The chest cavity was opened, aorta was isolated and transferred into a petri-jar containing Krebs or calcium free Krebs solution, aerated with carbogen (95% O2 and 5% CO2) and maintained in a water bath at 37 °C. The aorta cut into rings of about 2-4 mm long and the first four rings of the aorta distal to aortic arch were taken to avoid the difference in the amplitude of contraction.

The procedure described by Al-Habib and Shekha,( 2010) was followed with a slight modifications to study the vascular reactivity in isolated aorta. Two stainless steel wires were carefully passed through the lumen of the aortic rings, one of them was anchored to the base of glass organ bath chamber (Panlab/ Harvard, Model LE01046) and the other wires was attached to a force transducer (ADInstruments, Australia, Model MLT0420), connected to a transbridge amplifier (Quad Bridge Amplifier, Model FE 224, ADInstruments Pty Ltd., Australia), PowerLab Data Acquisition System (Model PL 3508, ADInstruments Pty Ltd., Australia) with computer running chart software (Version 7) (Model MLS060/7, ADInstruments, Australia) used for isometric tension measurement.

Prior to the experiment, the organ bath temperature was set at 37°C for at least one hour, followed by the addition 10 ml of Kreb’s with or calcium free solution to the tissue glass chamber. The preparation was aerated continuously with carbogen. Aortic rings were connected to the base of the chamber from one end and to the force transducer from the other end. The initial tension was set at 2 g weight and left for 60-90 min with changing the solution every 15 min. The aortic rings were initially exposed to 1µM (1*10^{-6} M) norepinephrin (NE) or 100µM (1*10^{-4} M) CaCl$_2$ to test their functional integrity and 10µM (1*10^{-5} M) acetylcholine (ACh) to test endothelium integrity. This was followed by changing the bath solution several times until a stable resting tone was recorded and then the experiments were started. The anti-contraction effects of two doses of EA (1*10^{-7} M and 3*10^{-7} M) on aortic rings post-contracted with different doses of NE (1*10^{-6}-10^{-5} M) or CaCl$_2$ (1*10^{-5}, 3*10^{-5}, 1*10^{-4}, 3*10^{-4}, 1*10^{-3}, 3*10^{-3} and 1*10^{-2} M) following an incubation period of 30 min. The present study included the following groups of experiments.

Group I

To study the anti-contraction effects of EA (1*10^{-7} M and 3*10^{-7} M) on endothelium-intact (+E) aortic rings, post-contracted with different doses of NE (1*10^{-9}-10^{-4} M), after pre-incubation of EA for 30 min.

Group II

To investigate the role of endothelial cells in anti-contraction effects of EA (1*10^{-7} M) and (3*10^{-7} M) on endothelium-denuded (-E) aortic rings, post-contracted with different doses of NE (1*10^{-9}-10^{-4} M), by gentle removal of endothelium. The removal of the endothelium was confirmed by the absence of relaxation induced by ACh (1*10^{-5} M) following NE (1*10^{-6} M) pre-contraction.

Group III

The role of endothelial nitric oxide (NO), cGMP and PGI$_2$ in association with anti-contraction effects of EA (1*10^{-7} M and 3*10^{-7} M) were evaluated, following pre-incubation of endothelium-intact aortic rings separately with each of NO synthase inhibitor, N-nitro-L-arginine methyl ester (L-NAME, 3*10^{-4} M), cGMP inhibitor, methylene blue (1*10^{-5} M) and PGI$_2$ inhibitor, indomethacin (3*10^{-5} M) in combination with EA (1*10^{-7} M and 3*10^{-7} M) and then post-contracted with different doses of NE (1*10^{-9}-10^{-4} M).

Group IV

To study the role of K$^+$ channels in the development of the anti-contraction effects of EA (1*10^{-7} M and 3*10^{-7} M) on endothelium-intact aortic rings, the aortic rings were pre-incubated separately with each of the following K$^+$ channels subtype blockers, K$_{Ca}$ channels blocker, (TEA, 1 mM), K$_{ATP}$ channels blocker, (GLIB, 1*10^{-5} M), K$_{Na}$ channels blocker, (BaCl$_2$, 1mM) and K$_{V}$ channels blocker, (4-AP, 1 mM) in combination with EA (1*10^{-7} M).
and $3 \times 10^{-7}$ M) post-contracted with different doses of NE ($1 \times 10^{-9}$-$10^{-4}$ M).

**Group V**

To elucidate the role of Ca$^{++}$ channels in anti-contraction effects induced by EA ($1 \times 10^{-7}$ M and $3 \times 10^{-7}$ M) in endothelium-intact aortic rings pre-incubated with L-type Ca$^{++}$ channels blocker (verapamil 10nM ($1 \times 10^{-8}$ M), in combination with EA and then post-contracted with different doses of CaCl$_2$ ($1 \times 10^{-5}$, $3 \times 10^{-5}$, $1 \times 10^{-4}$, $3 \times 10^{-4}$, $1 \times 10^{-3}$, $3 \times 10^{-3}$ and $1 \times 10^{-2}$ M) was studied.

**Statistical Analysis**

All data were expressed as means ± SEM and the median effective concentrations (EC$_{50}$) values are given as geometric mean with 95% confidence intervals (CI). The statistical analysis was performed using two-way analysis of variance (ANOVA) supported by Bonferroni test when carrying out a pairwise comparison between the same dose of different groups using Graphpad prism program (GraphPad Software, USA). P-values less than 0.05 were considered as statistically significant. In all figures, the symbols *, ** and *** indicate that the differences between means are significant at 0.05, 0.01 and 0.001 levels, respectively.

3- Results

**Anti-contraction Effect of Euscaphic Acid on Endothelium-intact Aorta**

Dose response-curves for EA anti-contraction effects on NE induced contraction in aortic rings are shown in Figure (1). Euscaphic acid at doses $1 \times 10^{-7}$ M and $3 \times 10^{-7}$ M caused a highly significant (P<0.001) anti-contraction effects on NE induced dose-dependent contraction at doses between $1 \times 10^{-7}$-$10^{-4}$ M in aortic rings as compared to the control rings. The Log EC$_{50}$, (LogEC$_{50}$ of CI 95%) and the % of contraction are shown in Table (1). Euscaphic acid at doses $1 \times 10^{-7}$ M and $3 \times 10^{-7}$ M produced a potent dose-dependent anti-contraction effect on NE induced contractions, with a LogEC$_{50}$ -5.400 mg/mL (LogEC$_{50}$ of CI 95% between -5.594 to -5.205) and -4.791 mg/mL (LogEC$_{50}$ of CI 95% between -5.477 to -4.105), respectively, whereas in absence of EA, it was -5.964 mg/mL (LogEC$_{50}$ of CI 95% between -6.092 to -5.835). The amplitude of contraction in NE induced contraction in aortic rings was reduced from 100 ± 0.002 %, in aortic rings pre-incubated with EA at concentration $1 \times 10^{-7}$ M and $3 \times 10^{-7}$ M to 83.993 ± 0.003 % and 75.527 ± 0.003 %, respectively.

**Fig. 1.** Cumulative dose-response curves for the anti-contraction effects of EA on NE induced contraction in the rat’s endothelium-intact aortic rings.
Table 1. The LogEC$_{50}$ (LogEC$_{50}$ of CI 95%) and contraction percent for the effects of pre-incubation with EA on NE post-contracted endothelium-intact aortic rings.

<table>
<thead>
<tr>
<th>Vasoconstrictor</th>
<th>NE</th>
<th>Treatments</th>
<th>Control</th>
<th>Euscaphic Acid 1X10$^{-7}$ M</th>
<th>Euscaphic Acid 3X10$^{-7}$ M</th>
</tr>
</thead>
<tbody>
<tr>
<td>LogEC$_{50}$</td>
<td></td>
<td></td>
<td>-5.964</td>
<td>-5.400</td>
<td>-4.791</td>
</tr>
<tr>
<td>LogEC$_{50}$ of CI 95%</td>
<td></td>
<td></td>
<td>-6.092 to -5.835</td>
<td>-5.594 to -5.205</td>
<td>-5.477 to -4.105</td>
</tr>
<tr>
<td>Contraction (%) ± SEM</td>
<td></td>
<td></td>
<td>100 ± 0.002</td>
<td>83.993 ± 0.003</td>
<td>75.527 ± 0.003</td>
</tr>
</tbody>
</table>

Anti-contraction Effect of Euscaphic Acid on Endothelium-denuded Aorta

Dose response-curves for the EA anti-contraction effects on NE induced contraction in endothelium-denuded aortic rings are shown in Figure (2). Both EA doses (1*10$^{-7}$ M and 3*10$^{-7}$ M) caused a highly significant (P<0.001) anti-contraction effects on NE induced dose-dependent contraction (between 1*10$^{-7}$ - 10$^{-4}$ M) in the aortic rings as compared to the control aortic rings. Euscaphic acid at a concentration of 1*10$^{-7}$ M produced a potent effect on NE induced contractions, with a LogEC$_{50}$ -5.493 mg/mL (LogEC$_{50}$ of CI 95% between -5.676 to -5.311), whereas EA at a concentration 3*10$^{-7}$ M produced a further, but limited anti-contraction effect with LogEC$_{50}$ -5.336 mg/mL (LogEC$_{50}$ of CI 95% between -5.496 to -5.175), as compared with that of the control (absence of EA) in which the LogEC$_{50}$ was -6.240 mg/mL (LogEC$_{50}$ of CI 95% between -6.424 to -6.056) (Figure 2 and Table 2). Also EA at a concentration of 1*10$^{-7}$ M showed much of its anti-contraction effect on aortic rings since the amplitude of contraction was reduced from 100.00 to 84.999 %, whereas at a higher EA dose (3*10$^{-7}$ M), it was further reduced, but to a lesser extent, to 80.086% (Table 2).

Fig. 2. Cumulative dose-response curves for the anti-contraction effects of EA on NE induced contraction in rat endothelium-denuded aortic rings.

Table 2. The LogEC$_{50}$ (LogEC$_{50}$ of CI 95%) and % of contraction for the effects of pre-incubation with EA on NE post-contracted endothelium-denuded aortic rings.

<table>
<thead>
<tr>
<th>Vasoconstrictor</th>
<th>NE</th>
<th>Treatments</th>
<th>Control</th>
<th>Euscaphic Acid 1X10$^{-7}$ M</th>
<th>Euscaphic Acid 3X10$^{-7}$ M</th>
</tr>
</thead>
<tbody>
<tr>
<td>LogEC$_{50}$</td>
<td></td>
<td></td>
<td>-6.240</td>
<td>-5.493</td>
<td>-5.336</td>
</tr>
<tr>
<td>LogEC$_{50}$ of CI 95%</td>
<td></td>
<td></td>
<td>-6.424 to -6.056</td>
<td>-5.676 to -5.311</td>
<td>-5.496 to -5.175</td>
</tr>
<tr>
<td>Contraction (%) ± SEM</td>
<td></td>
<td></td>
<td>100 ± 0.004</td>
<td>84.999 ± 0.006</td>
<td>80.086 ± 0.001</td>
</tr>
</tbody>
</table>

Anti-contraction Effect of EA on Aortic Rings Pre-incubated individually with L-NAME (NO Synthase Inhibitor), Indomethacin (PGI$_2$ Inhibitor) and Methylene blue (cGMP Inhibitor): Anti-contraction Effect of EA on Aortic Rings Pre-incubated with L-NAME (NO Synthase Inhibitor):

Dose response-curves for EA anti-contraction effects on NE induced contraction in aortic rings pre-incubated
with L-NAME (3*10^{-4} M) are shown in Figure (3). Euscaphic Acid at both doses 1*10^{-7} M and 3*10^{-7} M didn’t showed any significant effect on aortic rings pre-incubated with L-NAME, (the inhibitor of NO) and post-contracted with different doses of NE.

Fig. 3. Cumulative dose-response curves for the anti-contraction effects of EA on NE induced contraction in rat aortic rings pre-incubated with L-NAME (3*10^{-4} M).

**Anti-contraction Effect of EA on Endothelium-intact Aortic Rings Pre-incubated with Indomethacin (PGI_2 Inhibitor)**

Dose response-curves for the anti-contraction effects of EA on NE induced contraction in aortic rings pre-incubated with indomethacin (3*10^{-5} M) are shown in Figure (4). Euscaphic acid doses 1*10^{-7} M and 3*10^{-7} M produced a highly significant (P<0.001) anti-contraction effects on NE induced dose-dependent contraction (at doses between 1*10^{-6}–10^{-4} M) in aortic rings pre-incubated with indomethacin. The LogEC_{50}, (LogEC_{50} of CI 95%) and the % of contraction are shown in Table (3). Euscaphic acid at a concentration 1*10^{-7} M had more potent anti-contraction effect on NE induced contraction in aortic rings pre-incubated with indomethacin with LogEC_{50} -5.440 mg/ml (LogEC_{50} of CI 95% between -5.668 to -5.211). Furthermore, EA at a concentration of 3*10^{-7} M, also showed a further anti-contraction effect, but to a lesser extent, on NE post-contracted aortic rings pre-incubated with indomethacin with LogEC_{50} -5.250 mg/ml (LogEC_{50} of CI 95% between -5.705 to -4.796), while the LogEC_{50} was -5.692 mg/ml (LogEC_{50} of CI 95% between -5.871 to -5.513) in NE post-contracted aortic rings pre-incubated with indomethacin in the absence of EA. Euscaphic acid at a low concentration (1*10^{-7} M) produced most of its anti-contraction effect in which the amplitude of contraction was reduced from 100.00 to 81.122%, whereas at a higher concentration of EA (1*10^{-7} M), the amplitude of contraction was further reduced, but at a slower rate, to 76.468%.
Fig. 4. Cumulative dose-response curves for the anti-contraction effects of EA on NE induced contraction in rat aortic rings pre-incubated with indomethacin (3*10^-5 M).

Table 3. The LogEC_{50} (LogEC_{50} of CI 95%) and % of contraction for the effects of pre-incubation EA on NE post-contracted aortic rings pre-incubated with indomethacin (3*10^-5 M).

<table>
<thead>
<tr>
<th>Vasoconstrictor</th>
<th>NE Treatments</th>
<th>Control</th>
<th>Euscaphic Acid 1X10^{-7} M + Indomethacin 3X10^{-5} M</th>
<th>Euscaphic Acid 3X10^{-7} M + Indomethacin 3X10^{-5} M</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LogEC_{50}</td>
<td>-5.692</td>
<td>-5.440</td>
<td>-5.250</td>
</tr>
<tr>
<td></td>
<td>LogEC_{50} of CI 95%</td>
<td>-5.871 to -5.513</td>
<td>-5.668 to -5.211</td>
<td>-5.705 to -4.796</td>
</tr>
<tr>
<td></td>
<td>Contraction (%) ± SEM</td>
<td>100 ± 0.0005</td>
<td>81.122 ± 0.0006</td>
<td>76.468 ± 0.001</td>
</tr>
</tbody>
</table>

Anti-contraction effect of Euscaphic Acid on endothelium-intact aortic rings pre-incubated with methylene blue (cGMP Inhibitor)

Dose response-curves for EA anti-contraction effects on NE induced contraction in aortic rings pre-incubated with methylene blue (1*10^-5 M) are shown in Figure (5). Euscaphic acid doses between 1*10^{-7} M and 3*10^{-7} M caused highly significant (P<0.01 - < 0.001) anti-contraction effects on NE induced contraction in rats aortic rings at NE concentrations between 1*10^{-7} M and 1*10^{-8} to 10^{-4} M. The LogEC_{50} (LogEC_{50} of CI 95%) and the % of contraction are shown in Table (4). Euscaphic acid at a concentration of 1*10^{-7} M produced a moderate anti-contraction effect on NE induced contractions, with a LogEC_{50} -7.331 mg/ml (LogEC_{50} of CI 95% between -7.583 to -7.078), whereas EA at a higher concentration (3*10^{-7} M), produced a more potent anti-contraction effect with LogEC_{50} -7.147 mg/ml (LogEC_{50} of CI 95% between -7.396 to -6.898), as compared with the control experiment, in which the LogEC_{50} was -7.847 mg/ml (LogEC_{50} of CI 95% between -8.146 to -7.548) in absent of EA. Furthermore, also EA at concentrations 1*10^{-7} M and 3*10^{-7} M, produced potent anti-contraction effects on aortic rings since the amplitude of contraction was reduced from 100.00 (in the absence of EA) to 76.984 and 57.089%, respectively.
Fig. 5. Cumulative dose-response curves for the anti-contraction effects of EA on NE induced contraction in rat aortic rings pre-incubated with methylene blue (1*10^{-5} M).

Table 4. The LogEC_{50} (LogEC_{50} of CI 95%) and contraction (%) ± SEM for the effects of pre-incubation EA on NE post-contracted aortic rings pre-incubated with methylene blue (1*10^{-5} M).

<table>
<thead>
<tr>
<th>Vasoconstrictor</th>
<th>NE</th>
<th>Control</th>
<th>Methylene blue 1X10^{-5} M</th>
<th>Euscaphic Acid 1X10^{-7} M + Methylene blue 1X10^{-6} M</th>
<th>Euscaphic Acid 3X10^{-7} M + Methylene blue 1X10^{-5} M</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatments</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LogEC_{50}</td>
<td></td>
<td>-7.847</td>
<td>-7.331</td>
<td>-7.147</td>
<td></td>
</tr>
<tr>
<td>LogEC_{50} of CI 95%</td>
<td>-8.146 to -7.548</td>
<td>-7.583 to -7.078</td>
<td>-7.396 to -6.898</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contraction (%) ± SEM</td>
<td>100 ± 0.01</td>
<td>76.984 ± 0.008</td>
<td>57.089 ± 0.008</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Anti-contraction Effect of Euscaphic Acid on K^{+} Channels Subtype in Endothelium-intact Aorta Rings:

Anti-contraction Effect of Euscaphic Acid on K_{Ca} Channel in Endothelium-intact Aortic Rings

Dose response-curves for the EA anti-contraction effects on NE induced contraction in aortic rings pre-incubated with K_{Ca} channel blocker, TEA (1*10^{-3} M) are shown in Figure (6). Both EA doses, 1*10^{-7} M and 3*10^{-7} M, caused a significant (P<0.01) anti-contraction effect on NE induced dose-dependent contractions at doses between 1*10^{-6}-10^{-4} M and 1*10^{-7}-10^{-4} M, respectively. In aortic rings pre-incubated with TEA, EA at a concentration of 1*10^{-7} M produced a weak anti-contraction effect in NE induced contractions, with a LogEC_{50} -5.578 mg/ml (LogEC_{50} of CI 95% between -5.723 to -5.434), whereas at a higher EA concentration (3*10^{-7} M), a more potent anti-contraction effect was produced with LogEC_{50} -5.420 mg/ml (LogEC_{50} of CI 95% between -5.554 to -5.286), as compared with that of the control in which the LogEC_{50} was -5.725 mg/ml (LogEC_{50} of CI 95% between -5.901 to -5.549). Furthermore, EA at a concentration (1*10^{-7} M) showed a moderate anti-contraction effect on NE induced contraction in aortic rings pre-incubated with TEA since the amplitude of contraction was reduced from 100 ± 0.002 % to 91.479 ± 0.002 %, whereas at a higher EA dose (3*10^{-7} M), the anti-contraction effect on NE induced contraction in aortic rings pre-incubated with TEA was further enhanced, and reduced to 87.01 as compared with the control.
Fig. 6. Cumulative dose-response curves for the anti-contraction effects of EA on NE induced contraction in rat aortic rings pre-incubated with TEA (1*10^-3 M).

Table 5. The LogEC_{50} (LogEC_{50} of CI 95%) and contraction (%) ± SEM for the effects of pre-incubation with EA on NE post-contracted aortic rings pre-incubated with TEA (1*10^-3 M).

<table>
<thead>
<tr>
<th>Vasoconstrictor</th>
<th>Control</th>
<th>Euscaphic Acid 1X10^{-7} M + TEA 1X10^{-3} M</th>
<th>Euscaphic Acid 3X10^{-7} M + TEA 1X10^{-3} M</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatments</td>
<td>TEA 1X10^{-3} M</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Log EC_{50}</td>
<td>-5.725</td>
<td>-5.578</td>
<td>-5.420</td>
</tr>
<tr>
<td>Log EC_{50} of CI 95%</td>
<td>-5.901 to -5.549</td>
<td>-5.723 to -5.434</td>
<td>-5.554 to -5.286</td>
</tr>
<tr>
<td>Contraction (%) ± SEM</td>
<td>100.00 ± 0.002</td>
<td>91.479 ± 0.002</td>
<td>87.008 ± 0.001</td>
</tr>
</tbody>
</table>

Anti-contraction Effect of Euscaphic Acid on Endothelium-intact Aortic Rings Pre-incubated with GLIB (K\textsubscript{ATP} Channel Blocker)

Dose response-curves for the anti-contraction effects of EA on NE induced contraction in aortic rings pre-incubated with GLIB (1X10^{-5} M) are shown in Figures (7). Both EA doses, 1*10^{-7} M and 3*10^{-7} M used didn’t showed any significant effects on aortic rings pre-incubated with GLIB and post-contracted with different doses of NE.
Fig. 7. Cumulative dose-response curves for the effects of EA on NE induced contraction in rat aortic rings pre-incubated with GLIB (1*10^{-5} M).

Anti-contraction Effect of Euscaphic Acid on Endothelium-intact Aorta Rings Pre-incubated with BaCl₂ (K_{Ca} Channel Blocker)
Dose response-curves for anti-contraction effects of EA on NE induced contraction in aortic rings pre-incubated with BaCl₂ (1*10^{-3} M) are shown in Figure (8). Both EA doses 1*10^{-7} M and 3*10^{-7} M also didn’t showed any significant anti-contraction effect on aortic rings pre-incubated with BaCl₂ and induced contraction with different doses of NE.

Fig. 8. Cumulative dose-response curves for the anti-contraction effects of EA on NE induced contraction in rat aortic rings pre-incubated with BaCl₂ (1*10^{-7} M).
Anti-contraction Effect of Euscaphic Acid on Endothelium-intact Aorta Rings Pre-incubated with 4-AP (K\textsubscript{v} Channel Blocker)

Dose response-curves for anti-contraction effects of EA on NE induced contraction in aortic rings pre-incubated with 4-AP (1*10\textsuperscript{-3} M) are shown in Figure (9). Euscaphic acid doses 1*10\textsuperscript{-7} M and 3*10\textsuperscript{-7} M didn’t produce any significant anti-contraction effect on aortic rings pre-incubated with 4-AP and induced contraction with different doses of NE.

Fig. 9. Cumulative dose-response curves for the anti-contraction effects of EA on NE induced contraction in rat aortic rings pre-incubated with 4-AP (1*10\textsuperscript{-3} M).

Anti-contraction Effect of Euscaphic Acid on Endothelium-intact Aorta Rings Pre-incubated with Verapamil (L-type Ca\textsuperscript{++} Channel Blocker)

Dose response-curves for anti-contraction effects of EA on CaCl\textsubscript{2} induced contraction in aortic rings pre-incubated with verapamil (1*10\textsuperscript{-3} M) are shown in Figure (10). Euscaphic acid doses 1*10\textsuperscript{-7} M and 3*10\textsuperscript{-7} M produced a highly significant (P<0.001) anti-contraction effect on CaCl\textsubscript{2} induced contraction at concentrations between 1*10\textsuperscript{-4} and 1*10\textsuperscript{-2} M in aortic rings pre-incubated with verapamil. The LogEC\textsubscript{50}, (LogEC\textsubscript{50} of CI 95%) and the amplitude of contraction are shown in Table (6). Euscaphic acid at doses 1*10\textsuperscript{-7} M and 3*10\textsuperscript{-7} M produced significant (P<0.05 to 0.001) effects on CaCl\textsubscript{2} induced contraction in aortic rings pre-incubated with verapamil with LogEC\textsubscript{50} -3.740 mg/ml (LogEC\textsubscript{50} of CI 95% between -3.946 to -3.533) and -3.795 mg/ml (Log EC\textsubscript{50} of CI 95% between -3.961 to -3.628), respectively, as compared with the control experiments (in absence of EA), in which the LogEC\textsubscript{50} was -3.992 mg/ml (LogEC\textsubscript{50} of CI 95% between -4.088 to -3.897). Furthermore, EA at doses 1*10\textsuperscript{-7} M and 3*10\textsuperscript{-7} M produced strong anti-contraction effects on aortic rings pre-incubated with verapamil in which the amplitude of contraction was reduced from 100 ± 0.002 % (in the absence of EA) to 86.572 ± 0.001 % and 62.351 ± 0.0007 %, respectively.
Fig. 10. Cumulative dose-response curves for the anti-contraction effects of EA on CaCl₂ induced contraction in rat aortic rings pre-incubated with verapamil (1*10⁻⁸ M).

Table 6. The LogEC₅₀ (LogEC₅₀ of CI 95%) and contraction (%) ± SEM for the effects of pre-incubation with EA on CaCl₂ post-contracted aortic rings pre-incubated with verapamil (1*10⁻⁸ M).

<table>
<thead>
<tr>
<th>Vasoconstrictor</th>
<th>Control Verapamil 1X10⁻⁸ M</th>
<th>Euscaphic Acid 1X10⁻⁷ M + Verapamil 1X10⁻⁸ M</th>
<th>Euscaphic Acid 3X10⁻⁷ M + Verapamil 1X10⁻⁸ M</th>
</tr>
</thead>
<tbody>
<tr>
<td>LogEC₅₀</td>
<td>-3.992</td>
<td>-3.740</td>
<td>-3.795</td>
</tr>
<tr>
<td>LogEC₅₀ of CI 95%</td>
<td>-4.088 to -3.897</td>
<td>-3.946 to -3.533</td>
<td>-3.961 to -3.628</td>
</tr>
<tr>
<td>Contraction (%) ± SEM</td>
<td>100 ± 0.002</td>
<td>86.572 ± 0.001</td>
<td>62.351 ± 0.0007</td>
</tr>
</tbody>
</table>

4- Discussion

The current study was performed to investigate the possible anti-contraction effects of the novel triterpenoid EA isolated from *Crataegus azarolus var. aronia* on rat aortic smooth muscle at doses 1*10⁻⁷ M and 3*10⁻⁷ M. Euscaphic acid produced anti-contraction effects on aortic smooth muscle cells in association with endothelium-derived relaxing factors, K⁺ and L-type Ca²⁺ channels. The results of the current study represent the first report on the anti-contraction effect of EA on rat aortic rings smooth muscle, after its isolation for the first time from *C. azarolus*.

The results clearly indicated that the inhibitory effect of EA on the contraction of aortic smooth muscle in association with production of PGI₂, since the use of indomethacin (a nonspecific cyclooxygenase inhibitor) showed that PGI₂ plays an important role in EA vasodilator effect. Since no data are available on the effect of Euscaphic acid-induced relaxant effect on aortic smooth muscle, it is difficult to compare the results. However, Aguirre-Crespo et al., (2005) showed that the vasodilator effect of other triterpenoids isolated from *L. caulescens* was produced via cyclooxygenase synthase pathway. Wongsawatkul et al., (2008), demonstrated that the relaxant effect of *Spilanthes acmella* extract containing phenolic and triterpenoids is produced partially via endothelium induced PGI₂ production. Recently, Dood et al., (2013), suggested that the hawthorn induced the production of prostacyclin in rat smooth muscle cells (SMCs) and since EA is one of the active constituent of hawthorn, it may acts via the production of prostacyclin.

The mechanism by which PGI₂ inhibits smooth muscle contraction includes the activation of adenylyl cyclase via the specific cell surface IP receptor-coupled guanine nucleotide regulatory protein, Gs, which in turn elevates intracellular adenosine 3'-5'-cyclic monophosphate (cAMP) levels (Yamaki et al., 2001). Increased intracellular concentration of cAMP inhibits the sensitivity of the contractile proteins to Ca²⁺ ions (Clyman, 2006).
The results of the current study showed that cGMP has an important role on the anti-contraction effect of EA on aortic smooth muscle since the use of methylene blue (cGMP inhibitor) demonstrated clearly the role of cGMP in EA anti-contraction effects. According to our data, EA induce the production cGMP in endothelial cells, which in turn decreases the contraction of smooth muscle cells. This conclusion is supported by the observation that the guanylate cyclase inhibitor methylene blue reduced the relaxant effect of EA. Nitric oxide once released from the endothelium, diffuses into the arterial smooth muscle fibers to activate guanylate cyclase and thus increases cytoplasmic cGMP levels, leading to vasorelaxation in rat isolated mesenteric arteries (Chen et al., 1998). It has been reported that triterpenoids have significant endothelium-dependent vasorelaxant effect in rat aortic SMC through NO release (Rios et al., 2012), and since EA is triterpenoids, it may possibly act via inducing NO, which activate guanylate cyclase and in turn increases cGMP level and leading to vasorelaxation.

The mechanism of cGMP action in vasodilatation activity was explained by Gadelha de Cerqueira et al., (2012), which includes that cGMP activates intracellular effectors, such as protein kinase G (PKG), which causes diminishing of intracellular Ca$^{2+}$ ions and disassociation of actin and myosin filaments and ultimately leading to relaxation of the smooth muscle cells. Furthermore, they also explained the interaction of cGMP-cAMP cell signaling systems in the relaxation of smooth muscle. In other words, cGMP activates PKG, and then mediates vascular relaxation through phosphorylation of various targets (Hildebrand et al., 2013).

The results compiled from the effect of TEA (K$_{	ext{Ca}}$ channels blocker) on anti-contraction effect of EA on aortic smooth muscle cells indicate that K$_{	ext{Ca}}$ channels play a prominent role in increasing its anti-contraction effect and revealed that EA activate the K$_{	ext{Ca}}$ channels, but not other K$^+$ channels subtypes such as K$_{	ext{ATP}}$, K$_a$ and K$_c$ channels. These observations are in partial agreement with those reported by Chen et al., (1998), since they found that K$_c$ channels, using a potent K$_c$ channels inhibitor Iberiotoxin, plays a minor role in relaxant action hawthorn extract. Furthermore, they added that GLIB fail to change the vasorelaxation action of Crataegus extract in rat arterial SMCs.

The role of L-type Ca$^{2+}$ channel in smooth muscle contraction has been demonstrated by Fransen et al., (2012), and they showed that it is responsible for regulating the influx of Ca$^{2+}$ into muscle cells, which in turn stimulates smooth muscle contraction. Eusaphic acid used in the present study produced a sharp anti-contraction effect on aortic rings pre-incubated with verapamil (L-type Ca$^{2+}$ channel blocker). This proves that EA blocks the activity of L-type Ca$^{2+}$ channels which in turn leads to aortic vasorelaxation. Al-Surchi, (2010) working on the inhibitory effect of C. azarolus extract on rat’s aortic smooth muscle claimed that this effect may be due to the interference of active ingredient present in the extract such as triterpenoids either with Ca$^{2+}$ release from SR or with Ca$^{2+}$ influx through voltage gated L-type Ca$^{2+}$ channels located in the plasma membrane of smooth muscle cells. Furthermore, Chen et al., (1998) reported that hawthorn extract may have a direct inhibitory effect on Ca$^{2+}$ entry through voltage-sensitive Ca$^{2+}$ channels in smooth muscle cell membrane.

5- Conclusions

From the results of the current study it has been concluded that EA has anti-contraction and cardioprotective effects which are mediated possibly through enhancement of the production of endothelium-derived relaxing factors (particularly cGMP and PGI$_2$). Furthermore, EA also block Ca$^{2+}$ channels and ultimately Ca$^{2+}$ release from intracellular stores house and increase the K$^+$ conduction via increasing Kca channels activity. These observations might be justifying the medicinal use of EA which isolated from C. azarolus in hypertension and other cardiovascular diseases. However, more studies are required to establish the safety, efficacy and activity of this compound.

References


Fransen, P., Van Hove C.E., Langen J. and Bult H., (2012). Contraction by Ca2+ influx via the L-Type Ca2+ channel voltage window in mouse aortic segments is modulated by nitric oxide. licensee InTech.


The IISTE is a pioneer in the Open-Access hosting service and academic event management. The aim of the firm is Accelerating Global Knowledge Sharing.

More information about the firm can be found on the homepage: http://www.iiste.org

CALL FOR JOURNAL PAPERS

There are more than 30 peer-reviewed academic journals hosted under the hosting platform. Prospective authors of journals can find the submission instruction on the following page: http://www.iiste.org/journals/ All the journals articles are available online to the readers all over the world without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. Paper version of the journals is also available upon request of readers and authors.

MORE RESOURCES

Book publication information: http://www.iiste.org/book/

Academic conference: http://www.iiste.org/conference/upcoming-conferences-call-for-paper/

IISTE Knowledge Sharing Partners

EBSCO, Index Copernicus, Ulrich's Periodicals Directory, JournalTOCS, PKP Open Archives Harvester, Bielefeld Academic Search Engine, Elektronische Zeitschriftenbibliothek EZB, Open J-Gate, OCLC WorldCat, Universe Digital Library, NewJour, Google Scholar